Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence
To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor. Records of BC patients treated with RT + HT between 1995 and 2...
Saved in:
| Published in | International journal of hyperthermia Vol. 39; no. 1; pp. 1010 - 1016 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Taylor & Francis
31.12.2022
Taylor & Francis Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0265-6736 1464-5157 1464-5157 |
| DOI | 10.1080/02656736.2022.2103593 |
Cover
| Abstract | To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.
Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).
A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.
Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse. |
|---|---|
| AbstractList | To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.
Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).
A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.
Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse. Purpose To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.Materials and methods Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50–70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).Results A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.Conclusion Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse. To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.PURPOSETo evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor.Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).MATERIALS AND METHODSRecords of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS).A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.RESULTSA total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed.Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse.CONCLUSIONCombined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse. |
| Author | De-Colle, Chiara Beller, Anna Heinrich, Vanessa Voigt, Otilia Gani, Cihan Weidner, Nicola Gaupp, Stephan Müller, Arndt-Christian Lamprecht, Ulf Zips, Daniel Dohm, Oliver |
| Author_xml | – sequence: 1 givenname: Chiara orcidid: 0000-0003-4693-2148 surname: De-Colle fullname: De-Colle, Chiara organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 2 givenname: Anna surname: Beller fullname: Beller, Anna organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 3 givenname: Cihan surname: Gani fullname: Gani, Cihan organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 4 givenname: Nicola surname: Weidner fullname: Weidner, Nicola organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 5 givenname: Vanessa surname: Heinrich fullname: Heinrich, Vanessa organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 6 givenname: Ulf surname: Lamprecht fullname: Lamprecht, Ulf organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 7 givenname: Stephan surname: Gaupp fullname: Gaupp, Stephan organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 8 givenname: Otilia surname: Voigt fullname: Voigt, Otilia organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 9 givenname: Oliver surname: Dohm fullname: Dohm, Oliver organization: Department of Radiation Oncology, University Hospital and Medical Faculty Tübingen, Eberhard Karls University Tübingen – sequence: 10 givenname: Daniel surname: Zips fullname: Zips, Daniel organization: German Cancer Research Center (DKFZ), Heidelberg and German Cancer Consortium (DKTK) Partner Site Tübingen – sequence: 11 givenname: Arndt-Christian orcidid: 0000-0002-6539-0682 surname: Müller fullname: Müller, Arndt-Christian organization: Clinic of Radiation Oncology, Ludwisburg Hospital |
| BookMark | eNqFkUuLFDEURgsZwZ7RnyBk6abbPCpJBTfK4GNgQPCxDjev6YzVlfImjfS_t8qe2bjQ1YXL-T4u91x2F1OZYte9ZHTH6EBfU66k0kLtOOV8xxkV0ogn3Yb1qt9KJvVFt1mZ7Qo96y5rvaeU9pLrTff1C4Rc2j4izCcCUyD70xxxXRwykFSQOIxQG_Ew-Yhkhpbj1CqBRvb5bk8w1x-kJILRHxHjAj3vniYYa3zxMK-67x_ef7v-tL39_PHm-t3t1vdSta1WlDkzOCPNIMCknhsNgekUmRIpJkdBCEODAO2YEwyM1MGFwIT20vdJXHU3595Q4N7OmA-AJ1sg2z-LgncWsGU_RquZCbrn2vFlUN0PVAjmkpMDcOpEXLpenbtmLD-PsTZ7yNXHcYQplmO1XBk1KLl8bUHfnFGPpVaMyfrclq-UqSHk0TJqVy32UYtdtdgHLUta_pV-PPx_ubfnXJ4WKQf4VXAMtsFpLJhwcZOrFf-u-A0za6V1 |
| CitedBy_id | crossref_primary_10_2147_IJN_S426849 crossref_primary_10_1016_j_radonc_2024_110313 crossref_primary_10_1007_s40259_024_00669_y crossref_primary_10_1007_s12672_023_00697_0 crossref_primary_10_1016_j_ijrobp_2023_09_048 crossref_primary_10_3390_ijms252413664 crossref_primary_10_1016_j_ceramint_2024_07_013 |
| Cites_doi | 10.1080/02656730500271668 10.3109/02656736.2010.495104 10.1007/s10147-004-0395-3 10.1080/02656730400003393 10.1080/02656736.2018.1564155 10.1016/j.radonc.2011.07.020 10.1016/j.radonc.2021.12.036 10.1016/j.radonc.2015.10.017 10.1016/j.radonc.2015.04.019 10.1186/1471-2407-11-197 10.1016/0360-3016(92)90681-7 10.1007/s00066-018-1414-z 10.3390/cells10061436 10.1016/j.ijrobp.2007.06.035 10.1001/jamaoncol.2019.4320 10.1371/journal.pone.0120832 10.1016/j.ijrobp.2015.12.361 10.1016/0360-3016(89)90470-7 10.1200/JCO.1983.1.6.400 10.1016/j.radonc.2013.05.010 10.1080/02656736.2019.1660810 10.18632/oncotarget.6036 10.1200/JCO.2005.05.520 10.1002/1097-0142(19930801)72:3<774::AID-CNCR2820720323>3.0.CO;2-Y 10.1016/j.radonc.2013.03.026 10.1007/s00066-006-1496-x 10.1097/COC.0b013e31818af0b9 10.1016/j.adro.2020.100640 10.1016/0360-3016(96)00154-X 10.1016/j.surge.2014.03.001 10.1016/S0360-3016(00)01360-2 10.3389/fonc.2017.00132 10.3322/caac.21551 |
| ContentType | Journal Article |
| Copyright | 2022 The Author(s). Published with license by Taylor & Francis Group, LLC 2022 |
| Copyright_xml | – notice: 2022 The Author(s). Published with license by Taylor & Francis Group, LLC 2022 |
| DBID | 0YH AAYXX CITATION 7X8 DOA |
| DOI | 10.1080/02656736.2022.2103593 |
| DatabaseName | Taylor & Francis Open Access CrossRef MEDLINE - Academic Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1464-5157 |
| EndPage | 1016 |
| ExternalDocumentID | oai_doaj_org_article_719d7427b2d7407480331bfb58a20b3e 10_1080_02656736_2022_2103593 2103593 |
| Genre | Research Article |
| GrantInformation_xml | – fundername: Medizinischen Fakultät, Eberhard Karls Universität Tübingen grantid: E.05.00611.1 |
| GroupedDBID | --- 00X 0YH 29J 36B 4.4 5GY 5RE AALUX AAPXX AATTQ ABDBF ABLKL ACGEJ ACGFS ACUHS ADBBV ADCVX ADRBQ ADXPE AENEX AFKVX AIJEM AJWEG ALMA_UNASSIGNED_HOLDINGS BABNJ BCNDV BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EAP EAS EBB EBC EBD EBO EBS EBX EHN EMB EMK EMOBN EPL EPT ESX F5P GROUPED_DOAJ H13 HZ~ I-F KRBQP KSSTO KTTOD KWAYT L7B M4Z O9- OK1 P2P QZIEQ Q~Q SV3 TDBHL TFDNU TFL TFW TH9 TUS V1S ~1N AAYXX CITATION 7X8 |
| ID | FETCH-LOGICAL-c456t-7601b98b95983a9f4297ad17fe163fefb0a3390d3a7b1b31a957dbdd137c5c4f3 |
| IEDL.DBID | 0YH |
| ISSN | 0265-6736 1464-5157 |
| IngestDate | Wed Aug 27 01:20:11 EDT 2025 Fri Jul 11 08:00:05 EDT 2025 Thu Jul 24 02:03:24 EDT 2025 Thu Apr 24 23:06:49 EDT 2025 Wed Dec 25 09:04:59 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c456t-7601b98b95983a9f4297ad17fe163fefb0a3390d3a7b1b31a957dbdd137c5c4f3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4693-2148 0000-0002-6539-0682 |
| OpenAccessLink | https://www.tandfonline.com/doi/abs/10.1080/02656736.2022.2103593 |
| PQID | 2696865045 |
| PQPubID | 23479 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2696865045 crossref_primary_10_1080_02656736_2022_2103593 doaj_primary_oai_doaj_org_article_719d7427b2d7407480331bfb58a20b3e crossref_citationtrail_10_1080_02656736_2022_2103593 informaworld_taylorfrancis_310_1080_02656736_2022_2103593 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-12-31 |
| PublicationDateYYYYMMDD | 2022-12-31 |
| PublicationDate_xml | – month: 12 year: 2022 text: 2022-12-31 day: 31 |
| PublicationDecade | 2020 |
| PublicationTitle | International journal of hyperthermia |
| PublicationYear | 2022 |
| Publisher | Taylor & Francis Taylor & Francis Group |
| Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
| References | e_1_3_2_27_1 e_1_3_2_29_1 e_1_3_2_20_1 e_1_3_2_21_1 e_1_3_2_22_1 e_1_3_2_23_1 e_1_3_2_24_1 e_1_3_2_25_1 e_1_3_2_26_1 Overgaard J. (e_1_3_2_28_1) 1987; 163 e_1_3_2_16_1 e_1_3_2_9_1 e_1_3_2_17_1 e_1_3_2_8_1 e_1_3_2_18_1 e_1_3_2_7_1 e_1_3_2_19_1 e_1_3_2_2_1 e_1_3_2_31_1 e_1_3_2_30_1 e_1_3_2_10_1 e_1_3_2_33_1 e_1_3_2_11_1 e_1_3_2_32_1 e_1_3_2_6_1 e_1_3_2_12_1 e_1_3_2_35_1 e_1_3_2_5_1 e_1_3_2_13_1 Notter M (e_1_3_2_15_1) 2016; 33 e_1_3_2_34_1 e_1_3_2_4_1 e_1_3_2_14_1 e_1_3_2_37_1 e_1_3_2_3_1 e_1_3_2_36_1 |
| References_xml | – ident: e_1_3_2_5_1 doi: 10.1080/02656730500271668 – ident: e_1_3_2_10_1 doi: 10.3109/02656736.2010.495104 – ident: e_1_3_2_20_1 doi: 10.1007/s10147-004-0395-3 – volume: 163 start-page: 453 issue: 7 year: 1987 ident: e_1_3_2_28_1 article-title: Hyperthermia as an adjuvant to radiotherapy. Review of the randomized multicenter studies of the European Society for Hyperthermic Oncology publication-title: Strahlenther Onkol – ident: e_1_3_2_12_1 doi: 10.1080/02656730400003393 – ident: e_1_3_2_23_1 doi: 10.1080/02656736.2018.1564155 – ident: e_1_3_2_34_1 doi: 10.1016/j.radonc.2011.07.020 – ident: e_1_3_2_37_1 doi: 10.1016/j.radonc.2021.12.036 – ident: e_1_3_2_14_1 doi: 10.1016/j.radonc.2015.10.017 – ident: e_1_3_2_17_1 doi: 10.1016/j.radonc.2015.04.019 – ident: e_1_3_2_13_1 doi: 10.1186/1471-2407-11-197 – ident: e_1_3_2_21_1 doi: 10.1016/0360-3016(92)90681-7 – ident: e_1_3_2_22_1 doi: 10.1007/s00066-018-1414-z – ident: e_1_3_2_6_1 doi: 10.3390/cells10061436 – ident: e_1_3_2_11_1 doi: 10.1016/j.ijrobp.2007.06.035 – ident: e_1_3_2_32_1 doi: 10.1001/jamaoncol.2019.4320 – ident: e_1_3_2_3_1 doi: 10.1371/journal.pone.0120832 – ident: e_1_3_2_19_1 doi: 10.1016/j.ijrobp.2015.12.361 – ident: e_1_3_2_27_1 doi: 10.1016/0360-3016(89)90470-7 – ident: e_1_3_2_24_1 doi: 10.1200/JCO.1983.1.6.400 – volume: 33 start-page: 227–236 year: 2016 ident: e_1_3_2_15_1 article-title: Hypofractionated re-irradiation of large-sized recurrent breast cancer with thermography-controlled, contact-free water-filtered infra-red-A hyperthermia: a retrospective study of 73 patients publication-title: Int J Hyperthermia – ident: e_1_3_2_16_1 doi: 10.1016/j.radonc.2013.05.010 – ident: e_1_3_2_18_1 doi: 10.1080/02656736.2019.1660810 – ident: e_1_3_2_29_1 doi: 10.18632/oncotarget.6036 – ident: e_1_3_2_9_1 doi: 10.1200/JCO.2005.05.520 – ident: e_1_3_2_25_1 doi: 10.1002/1097-0142(19930801)72:3<774::AID-CNCR2820720323>3.0.CO;2-Y – ident: e_1_3_2_33_1 doi: 10.1016/j.radonc.2013.03.026 – ident: e_1_3_2_31_1 doi: 10.1007/s00066-006-1496-x – ident: e_1_3_2_35_1 doi: 10.1097/COC.0b013e31818af0b9 – ident: e_1_3_2_36_1 doi: 10.1016/j.adro.2020.100640 – ident: e_1_3_2_8_1 doi: 10.1016/0360-3016(96)00154-X – ident: e_1_3_2_26_1 doi: 10.1016/j.surge.2014.03.001 – ident: e_1_3_2_7_1 – ident: e_1_3_2_30_1 doi: 10.1016/S0360-3016(00)01360-2 – ident: e_1_3_2_4_1 doi: 10.3389/fonc.2017.00132 – ident: e_1_3_2_2_1 doi: 10.3322/caac.21551 |
| SSID | ssj0004527 |
| Score | 2.382327 |
| Snippet | To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients... Purpose To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC)... |
| SourceID | doaj proquest crossref informaworld |
| SourceType | Open Website Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1010 |
| SubjectTerms | Breast cancer hyperthermia radiotherapy recurrent breast cancer superficial hyperthermia |
| SummonAdditionalLinks | – databaseName: Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Nb9UwDI_QDogLYnyIx2AKEteOpk6W5jjQpglpHIBJu0VxPsQk6ENv3YH_HrtNx2CHd9mpktUoke3EdmL_LMQ70KgKqtBASBSg2DY2PRrVBNtHhdk4V7hQ-Ozz4em5_nRhLm61-uKcsBkeeGbce6tcovDNYkcfsnd9C6CwoOlD1yJkPn1b1y7B1F-ccDvfrpgpuX2p3WFUbaIxiWLDrjugiAeMg3-s0gTe_x906Z2jerI_J0_E4-o4yqN5wbviQR6eiodn9Wn8mfj6JaTLWk71W4Yhye8UYm6Y8PMySJpDIiegjzKyoDeyIqpeyTBKBi2WnGUu10Vu-Ap-KgJ8Ls5Pjr99PG1qx4QmkiM0Npzggq5HZ1wPwRUyNpZkYEsmt6vkgm0AcG2CYFEhqOCMTZiSAhtN1AVeiJ1hPeSXQhbyI_EQ-xiz1tq6PhWdHBjQxrW5KyuhF475WOHEuavFD68W1NHKaM-M9pXRK3FwM-zXjKexbcAHFsfNzwyHPRFISXxVEr9NSVbC3RamH6fbkDK3LvGwZQFvF8l72nr8nhKGvL6-8h0DC5GHq82r-1jknnjE884okq_Fzri5zm_I4xlxf1LuPzUu9Pw priority: 102 providerName: Directory of Open Access Journals |
| Title | Radiotherapy and hyperthermia for breast cancer patients at high risk of recurrence |
| URI | https://www.tandfonline.com/doi/abs/10.1080/02656736.2022.2103593 https://www.proquest.com/docview/2696865045 https://doaj.org/article/719d7427b2d7407480331bfb58a20b3e |
| Volume | 39 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NaxUxEA_agngRrRVf1RLB67abTdJsjiqWh1APasGeQiYfWrDvlX3bg_-9M9lsaRXpwdOyyya7mUkyH_nlF8beSAUig_CN9BEDFNOGpgctGm_6ICBpazNtFD75dLQ8VR-_6RlNuKmwSoqh80QUUeZqGtweNjMi7hDDBk1wJIzuuu4AYxaprbzPtjuD9ga7dHu2vEkYbqY0iy4o93kTz7-quWWeCov_Hxymf83ZxRAdP2aPqgfJ304qf8LupdUOe3BS18ifsi-ffTyv-6p-cWwk_4Gx5kAPLs49x29wICT6yANpfOCVWnXD_ciJvZgT3JyvMx8oF192A-6y0-MPX98vm3p0QhPQIxobQrqA7cFq20tvM1odg8owOaH_lVOG1ktp2yi9AQFSeKtNhBiFNEEHleUztrVar9JzxjM6lHAEfQhJKWVsH7OKVmqptG1TlxdMzRJzofKK0_EWP52Y6UeroB0J2lVBL9jBdbHLiVjjrgLvSB3XLxMvdnmwHr67OsycETZisG-gwwt6R30rpYAMuvfYCpkWzN5UphtLWiRPZ5g4eccPvJ4173AM0sKKX6X11cZ1xDCErq7Se_9R_wv2kG4nFsmXbGscrtIr9HhG2C99er_kC34D9LDz2A |
| linkProvider | Taylor & Francis |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKKwEXRHmoS4EaiWtKHNtr-whVq6Xt9gCtVE6Wn20l2EVpeuDfdyZxqgWEeuAUyYmdeMaO5xvPfCbkPReeZc9cxV0EgKLqUGkvWeWUDswnaUzGROH5yXR2Jg7P5flKLgyGVSKGzgNRRP-vxsmNzugxJO4D4AaJ8UgA75pmF0ALl4Y_IBtS6ymO9frbbJUxXA1-FtmHuY9ZPP9q5rf1qafx_4PE9K-fdr8SHTwlT4oJST8OOt8ka2nxjDycl03y5-TrFxevSmLVLwq9pJcANlss-HHlKLyDegxF72hAlbe0cKteU9dRpC-mGG9Ol5m26Izv0wFfkLOD_dO9WVXOTqgCmERdhaEu3mhvpNHcmQzLjgJtqJzAAMsp-9pxburInfLMc-aMVNHHyLgKMojMX5L1xXKRtgjNYFH6qdchJCGEMjpmEQ2XXEhTpyZPiBglZkMhFsfzLb5bNvKPFkFbFLQtgp6Q3btqPwdmjfsqfEJ13D2MxNh9wbK9sGWeWcVMBLSvfAMXMI90zTnz2UvtoBc8TYhZVabter9IHg4xsfyeD3g3at7CJMSdFbdIy5tr2yDFENi6Qr76j_Z3yKPZ6fzYHn8-Odomj_HWQCn5mqx37U16A-ZP59_24_sWhlb2WA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKK1VcqraAWFqKkbimxLFd20deq6UvIaASnCw_20plt8qmB_49M4lTFRDqgVMkJ3biGTv-xv78mZBXXHiWPXMVdxECFFWHSnvJKqd0YD5JYzJuFD45PZidicNvcmQTLgutEmPoPAhF9P9q7NzXMY-MuNcQNkikI0F01zT7ELNwafgDsiY1wHNo0vX32V3BcDVMs8ie5T5u4vlXMb8NT72K_x8apn_9s_uBaLpJNgqCpG8Gl2-RlTTfJusnZY38Efny2cXLsq_qJ4VK0guINVtM-HHpKLyDemSidzSgx1tapFWX1HUU1Ysp0s3pItMW5-L73YCPydn0w9d3s6ocnVAFQERdhUwXb7Q30mjuTIZRR4EzVE6Av3LKvnacmzpypzzznDkjVfQxMq6CDCLzJ2R1vpinp4RmAJT-wOsQkhBCGR2ziIZLLqSpU5MnRIwWs6HoiuPxFleWjfKjxdAWDW2LoSdk_zbb9SCscV-Gt-iO24dRF7tPWLTntnQzq5iJEOwr38AF0JGuOWc-e6kd1IKnCTF3nWm7flokD2eYWH7PB7wcPW-hD-LCipunxc3SNqgwBFBXyGf_Uf4Lsv7p_dQefzw92iEP8c4gKLlLVrv2Jj0H8NP5vb55_wL5O_WB |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Radiotherapy+and+hyperthermia+for+breast+cancer+patients+at+high+risk+of+recurrence&rft.jtitle=International+journal+of+hyperthermia&rft.au=De-Colle%2C+Chiara&rft.au=Beller%2C+Anna&rft.au=Gani%2C+Cihan&rft.au=Weidner%2C+Nicola&rft.date=2022-12-31&rft.pub=Taylor+%26+Francis&rft.issn=0265-6736&rft.eissn=1464-5157&rft.volume=39&rft.issue=1&rft.spage=1010&rft.epage=1016&rft_id=info:doi/10.1080%2F02656736.2022.2103593&rft.externalDBID=0YH&rft.externalDocID=2103593 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-6736&client=summon |